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Methods and Results:
 
 In this preliminary work, a retrospective analysis on
288 patients (227 men (79%), 61 women (21%)) who had received an ABPM in
our Heart Failure unit between 1999 and 2006 was made. Our study population,
with a mean age of 59.6 years consists of 45.2% ischemic cardiomyopathy, 42.6
% idiopathic dilated cardiomyopathy, 9.3 % hypertrophic cardiomyopathy, 2.9
% valvular cardiomyopathy. Almost all are symptomatic (NYHA I (8.3%) II
(48.2%) III (37.8%) IV (5.5%)) and average ejection fraction (EF) is 28.2%.
ABPM data and patient characteristics are studied in bivariate analysis: EF cor-
related positively with mean pulse pressure (PP) (daytime PP: r=0.47,p<0.001,
nightime PP: r=0.44,p<0.001), mean 24h-systolic blood pressure (SBP)(daytime
SBP: r=0.39, p<0.0001, nightime SBP:r=0.33, p<0.001) but no significance with
dipper status (p>0.05). Significative difference found for 24 h-PP (p<0.02),
dipper status between diabetic (n=60/288) and no diabetics patients. Creatinine
blood level correlated negatively with dipper status (r=-0.2, p<0.001). As regard
NYHA class, only one significative negative correlation exists with mean day-
time-SBP but not with PP or dipper status. 
 
Conclusions:
 
 Preliminary results of this study appear to be consistent with
medical knowledges. Our prospective study of survival, currently underway in
these patients, will allow us to identify prognosis interest of ABPM in CHF.
 
232
 
Comparative efficacy and safety of enoxaparin and fondaparinux in
non-high risk acute pulmonary embolism : an adjusted propensity
score analysis
Nicolas Meneveau, Vincent Descotes-Genon, Romain Chopard, Marie
France Séronde, Paul Luporsi, Florent Briand, Alexandre Guignier, Yvette
Bernard, Francois Schiele
CHU Besançon, Cardiologie, Besançon, France
Background: 
 
Guidelines recommend low molecular weight heparin
(LMWH) and fondaparinux (fonda) over unfractionated heparin (UFH) for ini-
tial treatment of acute pulmonary embolism (PE), except in patients (pts) at
high risk of bleeding & with severe renal dysfunction. No trial has assessed
the comparative efficacy of enoxaparin (enox) and fonda in this setting. 
 
Methods: 
 
Prospective, multicenter registry. Pts with proven recent PE
(symptom onset <15 days), treated with approved regimens of enox or fonda
were included. Pts with high risk PE, and those with recent or active bleeding,
recent surgery or stroke, or renal failure were excluded. We calculated a pro-
pensity score by logistic regression (i.e. predicted probability of treatment by
enox as opposed to fonda). Combined in-hospital endpoint was defined as
death, recurrent PE or major bleeding. Secondary endpoints were residual pul-
monary vascular obstruction (RPVO) at discharge and 6m, and 6m mortality. 
 
Results: 
 
Of 501 pts included between 2006 and 2010, 229(46%) received
enox and 272 (54%) received fonda. 5(2.2%) pts under enox had recurrent PE
vs 5 (1.8%) fonda pts (p=0.96). 13(5.7%) enox pts and 9(3.3%) fonda pts had
major bleeding (p=0.19), in-hospital mortality was 3.5% and 1.1% respec-
tively (p=0.07). During in-hospital stay, 19(8.3%) of pts treated with enox
reached at least 1 clinical endpoint vs 12(4.4%) fonda pts (p=0.07). After
adjusting on propensity score, there was no significant difference in death,
recurrent PE, major bleeding or combined endpoint (enox vs fonda, OR=1.45
[0.67-3.14]). RPVO at discharge was 28.4±14.6% in enox vs 27.2±13.9 in
fonda pts (p=0.57). There was no difference in RPVO at 6m. The 6m mortality
rate was 8.5% in enox pts vs 9.3% in fonda pts (p=0.76).
 
Conclusion: 
 
Our results suggest that enox and fonda can be used inter-
changeably, as efficacy and safety profiles are comparable in non-high risk
acute PE patients. Neither molecule appears to induce an excess bleeding risk
as compared to the other.
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Background:
 
 After an acute coronary syndrome (ACS), pharmacologic
therapy and lifestyle intervention (optimal medical therapy, OMT) are efficient
in reducing cardiovascular (CV) events. However, even if recommended sec-
ondary prevention goals are reached, a subset of patients still present CV
events.
 
Aim:
 
 To identify biological or cardiovascular markers predicting the
residual risk of CV events in post-ACS patients receiving OMT.
 
Patients and methods:
 
 990 patients benefited from an evaluation of risk
factors and atherosclerosis lesions, and optimization of long-term treatment
and education. Traditional CV risk factors and atheroma disease markers
(intima-media thickness (IMT), carotid atheroma, Ankle Brachial Index (ABI)
and number of coronary arteries with >50% stenosis) were evaluated 3 months
after ACS. CV events were recorded at follow-up (CV death, ACS, stroke,
heart failure, revascularization).
 
Results:
 
 At a median follow-up of 20 months, more than 80% of the
patients reached recommended prevention goals. 116 total CV events were
recorded. Diabetes was the only CV risk factor significantly associated with
CV events in multivariate analysis (including age, sex, hypertension, LDL
cholesterol, smoking, diabetes and hsCRP); HR 1,61 (1,09-2,39), p=0,017. In
multivariate analysis including CV risk factors and atheroma disease markers
(peripheral vascular disease (PVD) defined as ABI<0,9, carotid plaque > 50%,
IMT >0,7mm, 3-vessel and/or left main coronary disease), only PVD remained
significantly associated with CV events; HR 1,83 (1,02-3,31), p=0,04. The
number of vascular beds involved was associated with poorer prognosis: HR
for 3 vascular-beds disease 3,85 (1,72-8,63) p=0,001, given 1 vascular-bed
disease as a reference group.
 
Conclusion:
 
 In post-ACS patients with OMT, PVD and atheroma burden
represent powerful prognostic markers of CV events, while diabetes remains
the only independent marker of CV events among traditional CV risk factors. 
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Objectives: 
 
Cigarette smoking induces cardiovascular pathology and
worsens arterial stiffness. Arterial stiffness can be assessed non-invasively on
2 indices: pulse-wave velocity (PWV), indicating aortic stiffness, and augmen-
tation index (AIx), indicating aortic wave reflection. The impact of smoking
cessation (SC) nicotine replacement therapies (NRT) on arterial stiffness
remains unknown.
 
Methods: 
 
AIx and PWV were studied prospectively (SphygmoCor) in 26
long-term smokers (>10 cigarettes/day; mean age, 43±6 yrs) before (V1) and
28 and 56 days (V2,V3) after SC supported by NRT. Two-way repeated-mea-
sures ANOVA was used with patients serving their own controls on intention-
to-treat analysis. Abstinence was ascertained when exhaled carbon monoxide
(CO) was <10ppm; the quantity of NRT absorbed was assessed from the
serum cotinine level.
 
Results: 
 
16/24 patients (67%) were abstinent at end of study; 8/24 had
cut down on smoking; 2 were lost to follow-up. CO and serum cotinine
levels fell after SC. Mean AIx for the population as a whole was 23.4% at
V1, with significant early reduction by V2 (16.2%) and V3 (13.9%)
(ANOVA p<0.001). PWV, peripheral blood pressure and heart rate were
unchanged. Multivariate analysis failed to identify predictive factors among
baseline characteristics, cigarette addiction levels, or evolution of expired
CO or serum cotinine.
 
 
Conclusions: 
 
The improvement in
 
 
 
AIx and stability of PWV after SC with
NRT indicate improved peripheral vascular tone. This impact may account for
the early clinical benefit of SC observed even when associated to NRT.
